[go: up one dir, main page]

AU2002211717A1 - Stresscopins and their uses - Google Patents

Stresscopins and their uses

Info

Publication number
AU2002211717A1
AU2002211717A1 AU2002211717A AU1171702A AU2002211717A1 AU 2002211717 A1 AU2002211717 A1 AU 2002211717A1 AU 2002211717 A AU2002211717 A AU 2002211717A AU 1171702 A AU1171702 A AU 1171702A AU 2002211717 A1 AU2002211717 A1 AU 2002211717A1
Authority
AU
Australia
Prior art keywords
stresscopins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211717A
Inventor
Sheau Yu Hsu
Aaron J. W. Hsueh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2002211717A1 publication Critical patent/AU2002211717A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002211717A 2000-10-26 2001-10-10 Stresscopins and their uses Abandoned AU2002211717A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24412800P 2000-10-26 2000-10-26
US60/244,128 2000-10-26
US27661501P 2001-03-15 2001-03-15
US60/276,615 2001-03-15
PCT/US2001/032065 WO2002034934A2 (en) 2000-10-26 2001-10-10 Stresscopins and their uses

Publications (1)

Publication Number Publication Date
AU2002211717A1 true AU2002211717A1 (en) 2002-05-06

Family

ID=26936324

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211717A Abandoned AU2002211717A1 (en) 2000-10-26 2001-10-10 Stresscopins and their uses

Country Status (3)

Country Link
US (6) US20020082409A1 (en)
AU (1) AU2002211717A1 (en)
WO (1) WO2002034934A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1305334B1 (en) 2000-08-04 2008-09-17 Research Development Foundation Urocortin proteins and uses thereof
IL154553A0 (en) * 2001-03-15 2003-09-17 Res Dev Foundation Urocortin-iii and uses thereof
JP2006500002A (en) 2001-12-03 2006-01-05 メタボレックス インコーポレーティッド Methods and reagents for diagnosis and treatment of diabetes
US7879111B2 (en) * 2006-11-02 2011-02-01 Sony Corporation System and method for RFID transfer of MAC, keys
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
GR1004664B (en) * 2002-11-26 2004-09-02 Bionature E A Ltd The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references
KR100693528B1 (en) * 2004-10-29 2007-03-14 주식회사 팬택 Wireless communication terminal with power delay authorization function
US7815905B2 (en) * 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
GB2442001A (en) * 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2009033773A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent
WO2009040029A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
RU2010114061A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) APPLICATION OF His-Ser-Leu-Gly-Lys-Trp-Leu-His-Pro-Asp-Lys-Phe PEPIDID INDIVIDUALLY OR IN COMBINATION WITH A Gly-Arg-Gly-Asp-Asn-Pro-OH PEPTIDE AS A THERAPEUTIC
EP2197463A2 (en) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
CN102272151B (en) * 2008-11-04 2014-08-20 詹森药业有限公司 Crhr2 peptide agonists and uses thereof
JP2013510167A (en) * 2009-11-04 2013-03-21 ヤンセン ファーマシューティカ エヌ．ベー． Treatment of heart failure with stress-copin-like peptides
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
JOP20170153A1 (en) 2016-07-15 2019-01-30 Lilly Co Eli Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000063A2 (en) * 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
EP1305334B1 (en) * 2000-08-04 2008-09-17 Research Development Foundation Urocortin proteins and uses thereof
IL154553A0 (en) * 2001-03-15 2003-09-17 Res Dev Foundation Urocortin-iii and uses thereof

Also Published As

Publication number Publication date
US20020082409A1 (en) 2002-06-27
US20040127415A1 (en) 2004-07-01
US7829330B2 (en) 2010-11-09
US8481686B2 (en) 2013-07-09
WO2002034934A2 (en) 2002-05-02
US7291341B2 (en) 2007-11-06
US20150307571A1 (en) 2015-10-29
US20120066775A1 (en) 2012-03-15
US20150025125A1 (en) 2015-01-22
US20080145927A1 (en) 2008-06-19
WO2002034934A3 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2001294814A1 (en) Pumpcn compositions and uses thereof
AU2001213236A1 (en) Mini-cyclone biocollector and concentrator
AU2000267458A1 (en) Hypercomputer
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2001220246A1 (en) Neckphone
AU2001240637A1 (en) Novel imidazotriazinones and the use thereof
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
AU2002211717A1 (en) Stresscopins and their uses
AU2001272011A1 (en) Siderophores-producing bifidobacteria thereby and uses thereof
AU2001261750A1 (en) Laminate and its use
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001243394A1 (en) Compounds and methods
AU7458201A (en) Laminate and use thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2001229439A1 (en) Bioconjugates and uses thereof
AUPQ872300A0 (en) Compounds and methods
AU2001278951A1 (en) Compounds and methods
AU2001269276A1 (en) Drills and their manufacture
AU4432001A (en) Trityl-type compounds and their use
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2001226668A1 (en) Crankshaft-starter-generator
AU2002235277A1 (en) Compounds and methods